Vaccines for Preventing Ebola Virus Disease

Overview

Journal Cochrane Database Syst Rev

Publisher Wiley

Specialties General Medicine
Health Services

Date 2024 Nov 19

PMID 39560047

Authors

Rebecca Kuehn

Hannah Ryan

Kevin C Okwaraeke

Susan Gould

Marty Chaplin

Matthew Riley

Lance Turtle

Shevin T Jacob

Tom Fletcher

Affiliations

Soon will be listed here.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of vaccines to prevent Ebola virus disease in people who have been, or have potentially been, exposed to Ebola virus.

References

Balshem H, Helfand M, Schunemann H, Oxman A, Kunz R, Brozek J . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64(4):401-6. DOI: 10.1016/j.jclinepi.2010.07.015. View

Goeijenbier M, van Kampen J, Reusken C, Koopmans M, van Gorp E . Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis. Neth J Med. 2014; 72(9):442-8. View

Woolsey C, Geisbert T . Current state of Ebola virus vaccines: A snapshot. PLoS Pathog. 2021; 17(12):e1010078. PMC: 8659338. DOI: 10.1371/journal.ppat.1010078. View

Vetter P, Kaiser L, Schibler M, Ciglenecki I, Bausch D . Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis. 2016; 16(6):e82-e91. DOI: 10.1016/S1473-3099(16)00077-3. View

West T, Andre-von Arnim A . Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc. 2014; 11(9):1341-50. DOI: 10.1513/AnnalsATS.201410-481PS. View

Bah E, Lamah M, Fletcher T, Jacob S, Brett-Major D, Sall A . Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2014; 372(1):40-7. DOI: 10.1056/NEJMoa1411249. View

Zhu F, Wurie A, Hou L, Liang Q, Li Y, Russell J . Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2016; 389(10069):621-628. DOI: 10.1016/S0140-6736(16)32617-4. View

Campbell M, McKenzie J, Sowden A, Katikireddi S, Brennan S, Ellis S . Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020; 368:l6890. PMC: 7190266. DOI: 10.1136/bmj.l6890. View

Dolzhikova I, Zubkova O, Tukhvatulin A, Dzharullaeva A, Tukhvatulina N, Shcheblyakov D . Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother. 2017; 13(3):613-620. PMC: 5360131. DOI: 10.1080/21645515.2016.1238535. View

10.

Elston J, Cartwright C, Ndumbi P, Wright J . The health impact of the 2014-15 Ebola outbreak. Public Health. 2017; 143:60-70. DOI: 10.1016/j.puhe.2016.10.020. View

11.

Masterson S, Lobel L, Carroll M, Wass M, Michaelis M . Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies. Front Immunol. 2018; 9:1025. PMC: 5954026. DOI: 10.3389/fimmu.2018.01025. View

12.

Mulangu S, Dodd L, Davey Jr R, Mbaya O, Proschan M, Mukadi D . A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019; 381(24):2293-2303. PMC: 10680050. DOI: 10.1056/NEJMoa1910993. View

13.

Zhu F, Hou L, Li J, Wu S, Liu P, Zhang G . Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015; 385(9984):2272-9. DOI: 10.1016/S0140-6736(15)60553-0. View

14.

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

15.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021; 134:178-189. DOI: 10.1016/j.jclinepi.2021.03.001. View

16.

Lamontagne F, Fowler R, Adhikari N, Murthy S, Brett-Major D, Jacobs M . Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet. 2017; 391(10121):700-708. PMC: 6636325. DOI: 10.1016/S0140-6736(17)31795-6. View

17.

Coulborn R, Bastard M, Peyraud N, Gignoux E, Luquero F, Guai B . Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo. Lancet Infect Dis. 2024; 24(6):602-610. DOI: 10.1016/S1473-3099(23)00819-8. View

18.

Malvy D, McElroy A, de Clerck H, Gunther S, van Griensven J . Ebola virus disease. Lancet. 2019; 393(10174):936-948. DOI: 10.1016/S0140-6736(18)33132-5. View

19.

Gao Y, Zhao Y, Guyatt G, Fowler R, Kojan R, Ge L . Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. Lancet Microbe. 2022; 3(9):e683-e692. PMC: 9441701. DOI: 10.1016/S2666-5247(22)00123-9. View

20.

McMahon S, Ho L, Brown H, Miller L, Ansumana R, Kennedy C . Healthcare providers on the frontlines: a qualitative investigation of the social and emotional impact of delivering health services during Sierra Leone's Ebola epidemic. Health Policy Plan. 2016; 31(9):1232-9. PMC: 5035780. DOI: 10.1093/heapol/czw055. View